Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical reports developments in robotic-assisted minimally invasive care, centered on its da Vinci surgical systems, da Vinci 5, da Vinci SP, and Ion Endoluminal System. Company news commonly covers procedure volume, system placements, installed-base growth, instruments and accessories revenue, operating lease placements, and share repurchase activity.
Updates also include FDA clearances that expand indications for Intuitive platforms, such as cardiac procedures for da Vinci 5 and additional procedures for da Vinci SP. News about the company also reflects completed commercial expansion in Europe, including direct operations for da Vinci and Ion distribution in Southern European markets.
Intuitive (Nasdaq: ISRG) reported strong Q1 2021 results, with revenue reaching $1.29 billion, marking an 18% increase year-over-year. The company shipped 298 da Vinci Surgical Systems, a 26% rise from last year, and achieved an installed base of 6,142 systems, up 8%. GAAP net income also grew to $426 million ($3.51 per diluted share), compared to $314 million ($2.62 per diluted share) in Q1 2020. Instruments and accessories revenue rose 14% to $706 million, driven by a 16% increase in da Vinci procedure volume.
Intuitive (Nasdaq: ISRG) reported Q4 2020 revenue of $1.33 billion, up 4% year-over-year. The company experienced a 6% increase in da Vinci procedures but a 3% drop in system shipments, reflecting COVID-19 disruptions. GAAP net income rose to $365 million ($3.02 per diluted share), compared to $358 million ($2.99 per diluted share) in Q4 2019. Operating expenses included a $25 million contribution to the Intuitive Foundation. The installed base of da Vinci systems grew by 7% to 5,989 systems.
Intuitive (Nasdaq: ISRG) reported preliminary fourth quarter and full year 2020 financial results, revealing a 4% revenue increase to approximately $1.33 billion for Q4, while full year revenue declined 3% to about $4.36 billion. Worldwide da Vinci procedures rose by 6% in Q4 and 1% for the year, despite COVID-19 disruptions. However, surgical system shipments fell to 326 in Q4 2020 from 336 in 2019 and totaled 936 for the year, down from 1,119. Notably, instruments and accessories revenue grew by 11% in Q4, totaling approximately $747 million.
Intuitive Surgical (Nasdaq: ISRG) has launched Intuitive Ventures, a $100 million fund aimed at investing in minimally invasive care innovations. This fund will focus on early-stage companies in digital tools, precision diagnostics, and therapeutic technologies. Julian Nikolchev, President of Intuitive Ventures, emphasizes the goal to enhance the continuum of care. With a leadership team experienced in healthcare investment, Intuitive Ventures aims to leverage industry expertise to drive positive healthcare outcomes.
Intuitive (Nasdaq: ISRG) reported Q3 financial results for 2020, revealing a revenue decline of 4% year-over-year to $1,078 million. The company shipped 195 da Vinci Surgical Systems, a decrease of 29% compared to 2019. Despite challenges from COVID-19, da Vinci procedures increased by 7%, and the installed base grew to 5,865 systems, up 8% from last year. Net income fell to $314 million, or $2.60 per diluted share, down from $397 million, or $3.33 per diluted share in Q3 2019. The company also launched a $100 million fund for healthcare innovations.
Intuitive (Nasdaq: ISRG) reported Q2 2020 revenue of $852 million, down 22% from $1,099 million in Q2 2019, heavily impacted by the COVID-19 pandemic. Worldwide da Vinci procedures declined 19%, and the shipment of da Vinci Surgical Systems fell 35% to 178 units. The installed base of systems grew 9% to 5,764. GAAP net income was $68 million ($0.57/share), down from $318 million ($2.67/share) last year. The company ended the quarter with $6.1 billion in cash and equivalents. Despite challenges, Intuitive launched an 'Extended Use Program' for instruments to improve economic efficacy.
Summary not available.
Summary not available.